Literature DB >> 27704620

The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.

Samira Kalayi Nia1, Shayan Ziaee1, Mohammad Ali Boroumand2, Maryam Sotudeh Anvari2, Leyla Pourgholi1, Arash Jalali3.   

Abstract

BACKGROUND: The association between genetic variations of vascular endothelial growth factor (VEGF) gene and the risk for atherosclerosis has been hypothesized. We aimed to assess the relationship between rs2010963 (+405 C/G) polymorphism and presence, severity, and outcome of coronary artery disease (CAD) in an Iranian cohort.
METHODS: Genotyping of VEGF rs2010963 polymorphism was performed on 520 individuals, comprising 347 patients with documented coronary artery disease based on angiography report and 173 individuals with normal coronary arteries, using the TaqMan real-time PCR method. In final, 484 subjects were followed up over a 5-year period for cardiovascular-related outcomes.
RESULTS: C allele of VEGF rs2010963 polymorphism was related to increase risk for CAD and also slightly to 5-year cardiovascular mortality. The 5-year survival in C and G allele subgroups were 92.3% and 94.3% in CAD group and 95.7% and 98.0% in non-CAD group, respectively.
CONCLUSIONS: Vascular endothelial growth factor rs2010963 polymorphism may be associated with the presence of CAD and its long-term survival, but not with its severity. To the best of our knowledge, this is the first report of genetic association between rs2010963 SNP and CAD-related death. It can be thus suggested that rs2010963 VEGF gene can be considered as a genetic risk predictor for CAD and its outcomes.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Gensini score; coronary artery disease; gene; mortality; vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 27704620      PMCID: PMC6816936          DOI: 10.1002/jcla.22066

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  33 in total

1.  Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening.

Authors:  E Van Belle; F O Tio; D Chen; L Maillard; D Chen; M Kearney; J M Isner
Journal:  J Am Coll Cardiol       Date:  1997-05       Impact factor: 24.094

2.  Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.

Authors:  I J Brogan; N Khan; K Isaac; J A Hutchinson; V Pravica; I V Hutchinson
Journal:  Hum Immunol       Date:  1999-12       Impact factor: 2.850

3.  Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease.

Authors:  Atousa Moradzadegan; Asad Vaisi-Raygani; Abdolrahim Nikzamir; Zohreh Rahimi
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-02-06       Impact factor: 1.636

4.  Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation.

Authors:  E Van Belle; L Maillard; F O Tio; J M Isner
Journal:  Biochem Biophys Res Commun       Date:  1997-06-18       Impact factor: 3.575

5.  A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels.

Authors:  W Renner; S Kotschan; C Hoffmann; B Obermayer-Pietsch; E Pilger
Journal:  J Vasc Res       Date:  2000 Nov-Dec       Impact factor: 1.934

6.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.

Authors:  Takuya Awata; Kiyoaki Inoue; Susumu Kurihara; Tomoko Ohkubo; Masaki Watanabe; Kouichi Inukai; Ikuo Inoue; Shigehiro Katayama
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

7.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury.

Authors:  D F Lazarous; M Shou; M Scheinowitz; E Hodge; V Thirumurti; A N Kitsiou; J A Stiber; A D Lobo; S Hunsberger; E Guetta; S E Epstein; E F Unger
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

9.  Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction.

Authors:  Panagiotis Douvaras; Dionisios G Antonatos; Kiriaki Kekou; Sotirios Patsilinakos; George Chouliaras; Apostolos Christou; Anastasios Andrikou; Emmanuel Kanavakis
Journal:  Cardiology       Date:  2009-03-31       Impact factor: 1.869

10.  Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

Authors:  V Vincenti; C Cassano; M Rocchi; G Persico
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

View more
  2 in total

1.  Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta-analysis.

Authors:  Wen-Qi Ma; Ying Wang; Xi-Qiong Han; Yi Zhu; Nai-Feng Liu
Journal:  BMC Med Genet       Date:  2018-07-04       Impact factor: 2.103

2.  Dietary total antioxidant capacity significantly interacts with 6-P21 rs2010963 gene polymorphisms in terms of cardio-metabolic risk factors in patients with metabolic syndrome.

Authors:  Mahdieh Abbasalizad Farhangi
Journal:  BMC Res Notes       Date:  2020-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.